Acutus Medical, Inc. Overview
Pro stress-test →Acutus Medical designs, manufactures, and markets tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company recently executed a strategic pivot, exiting its core electrophysiology mapping and ablation business in 2024 to focus on left-heart access products distributed through partnerships.
Strategic Profile
Pro stress-test →The company shifted focus to left-heart access products with revenue up 156% year-over-year in Q3 2024, achieving gross margin improvement to 5% from negative 44%. The company no longer provides financial guidance due to its plan to realign resources to support the left-heart access distribution business and exit from electrophysiology mapping and ablation businesses. Trading on OTC markets as of 2026, Acutus is in transition with limited liquidity and financial headroom.
Competitive Landscape
Pro stress-test →Acutus originally competed in cardiac ablation mapping against Abbott (EnSite mapping systems) and Biosense Webster (CARTO mapping). Following its 2024 exit from mapping/ablation, the company now competes as a left-heart access product distributor, facing established medical device distributors and direct competitors in transseptal crossing tools. The pivot significantly reduces competitive positioning in the broader $15B+ atrial ablation market.
Industry Context
Acutus Medical, Inc. operates in Cardiac arrhythmia treatment devices.
Key facts
Founded: 2011 · Headquarters: Carlsbad, California, US · Employees: N/A · Revenue: $XXM (2024 undisclosed; Q3 2024 showing growth from left-heart access) · Market cap: N/A